Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Mucosal Healing in Ulcerative Colitis: Where do we Stand?

Author(s): Gionata Fiorino, Monica Cesarini, Amedeo Indriolo and Alberto Malesci

Volume 12, Issue 10, 2011

Page: [1417 - 1423] Pages: 7

DOI: 10.2174/138945011796818216

Price: $65

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited.

This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.

Keywords: Ulcerative Colitis, Inflammatory bowel disease, Mucosal healing, Colonoscopy, Medical therapy, MMX, 5-ASA


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy